Commit Biologics is developing the Bispecific Complement Engaging (BiCE™) platform, a modular system that uses single‑domain antibodies to engage C1q and direct complement activation against tumor and autoimmune targets. The technology can arm conventional antibodies to enhance complement‑mediated cytotoxicity and modulate innate and adaptive immune responses. Commit spun out of Aarhus University and builds on more than three decades of research. Since emerging from stealth last May, the company has progressed its platform toward drug candidate selection. Proceeds from the recent financing will be used to advance BiCE and work toward drug candidate (DC) selection. The company says the extension of funding extends its cash runway into late 2026. Commit Biologics develops therapies that activate the complement system to kill specific target cells, with applications in cancer and autoimmune disease. Its core product is the Bispecific Complement Engaging (BiCE™) platform, a modular system that can arm antibodies to direct the complement system to selectively kill cancer cells or immune cells that drive autoimmune diseases. The platform is designed to leverage established antibodies, which the company says can cut development times and reduce risk. Commit plans to use the €16M seed financing to accelerate development of the BiCE™ platform. The company was spun out of Aarhus University and builds on more than three decades of research into complement biology. Commit is led by CEO Krishna Polu. Commit Biologics is developing the BiCE technology to fight cancer. The company announced it has received a 5M DKK Innobooster grant from the Innovation Fund Denmark (IFD). The grant is intended to support further development of the BiCE technology. Aarhus University Technology Transfer posted congratulations on LinkedIn about the boost. The funding is presented as an Innobooster grant rather than equity or debt; no additional financial details were disclosed in the article.

Total raised

$24M

Funding rounds

3

Latest round

Seed

Latest activity

Jan 2025